Adocia SA (A89.F)

6,23 +0,09 (+1,47%) Börsenschluss: 05:20PM CEST

Adocia SA

115 Avenue Lacassagne
Lyon 69003
France
33 4 72 61 06 10
https://www.adocia.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 78

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Gérard Soula M.B.A., Ph.D.	Co-Founder & Chairman of the Board	247,58k	N/A	1945
Mr. Olivier Soula M.B.A., Ph.D.	Co-Founder, CEO & Director	278,63k	N/A	1970
Ms. Valérie Danaguezian	Chief Financial Officer	N/A	N/A	N/A
Mr. Mathieu-William Gilbert	Chief Operating Officer	N/A	N/A	N/A
Jeremy Benattar Eng., Pharm.D.	Marketing & Strategy Director	N/A	N/A	N/A
Ms. Geraldine Favre Soula	Director of Human Resources	N/A	N/A	N/A
Dr. Bertrand Alluis	Head of the Analysis Department and Project Manager	N/A	N/A	N/A
Dr. David Duracher	Head of the Pharmaceutical Development & Physical Chemistry Departments and Project Manager	N/A	N/A	N/A
Dr. Richard Charvet	Head of Chemistry Department & Project Manager	N/A	N/A	N/A
Dr. Grégory Meiffren	Head of the Biology Department & Project Manager	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of prandial insulin with pramlintide, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-term delivery of therapeutic agents. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Corporate Governance

Adocia SAs ISS Governance QualityScore, Stand 1. Juli 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.